Pharmafile Logo

Focus on Rare Diseases

As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond.

- PMLiVE
The US government passed the Orphan Drug Act in 1983, and it was subsequently adopted in other key markets, most notably in Japan in 1993 and the European Union in 2000. Growth in this sector has remained around 12% annually, which is more than double that experienced in the general drug market. According to the 2015 Orphan Drug Report, worldwide orphan drug sales will reach $178 billion by 2020 and will account for 20% of all prescription drug sales by 2020*. 

The trend is clear: as science and technology advances, and the rise of the internet and social media enables patients and researchers to gather and share information more effectively, we are seeing treatments for rare diseases that only a few years ago would have led to an early death. 

Alison Cantle, Rare Disease Business Unit Director at Lucid Group, explains what this means for medical education agencies: “As pharmaceutical organisations focus on personalised medicine, the need for rare disease expertise in their medical education agencies is paramount. Lucid recognised this and structured its business last year to create a unit specialising in rare diseases.” 

Within this unit, Lucid Group had recruited a team of highly skilled medical writers who combine a deep and robust understanding of the science with experience of working with rare disease specialists across the globe.

“Our rare disease team understands the cornerstones of rare disease education and what makes it different from other therapy areas. It is essential to build networks and enable best practice sharing,” Alison explains. “And in rare disease, more so than in any other therapy area, the choice of agency is crucial, as often it is your agency who represents your organisation at the communication level – so its voice has to be your voice.” 

Patients who have a rare disease face difficulty in every step of medical care, including diagnosis, treatment and preserving quality of life. Sometimes, patients go years without receiving the correct diagnosis for their condition. So raising awareness, improving time to diagnosis, getting patients to the right care, and improving family and emotional support and reimbursement are just some of the areas where medical education agencies can support pharma clients. 

Lucid’s Rare Disease Business Unit currently works with clients in Fabry disease, Pompe disease, Gaucher disease, cystinosis and PKU.  For further information about working with Lucid’s Rare Disease Business Unit, please call Alison on 01494 552078 or email alison@lucid-uk.com. 

* EvaluatePharma Orphan Drug Report 2015

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

Lucid celebrates summer in style at their annual summer meeting

Lucid held their annual Summer Meeting last week. The event is all about taking the time out to celebrate colleagues, teams, and all they have achieved in the year so...

Data Visualisation

Last week’s Thirsty Thursday was all about data visualisation and was hosted by Katherine Mantell, Managing Director of Leading Edge – part of the Lucid family of companies.Katherine started the session with...

The True Potential of Mobile Health Tech

In a recent edition of PME, Dennis O’Brien, Lucid CEO and co-founder, discusses the potential of mobile health in improving patient outcomes – a goal that is at the heart...

Lucid’s magic touch is recognised, winning both Communiqué Medical Education Consultancy of the Year and Communiqué Communications Consultancy of the Year 2018

Lucid’s pioneering and patient-centric approach to strategic medical communications was recognised yesterday as they scooped  a total of four awards. These included: Excellence in Communications via Meetings for OptiMiSe –...

Improving Outcomes – Patient Engagement & Activation

Last week, Lucid launched its first Thirsty Thursday session, during which everyone gets an opportunity to quench their thirst for knowledge and learn about new industry trends and techniques. Last...

Patient outcomes in practice: delivering value that transforms lives

In this month’s PME, Lucid CEO and co-founder, Dennis O’Brien, and Managing Director, Louise Verrall, discuss ‘Patient outcomes in practice: delivering value that transforms lives’. In response to the increasing...

Lucid are bringing magic to the North West with three new hires

Lucid Group are spreading their magic to the North West with three new hires, bolstering their client services and delivery teams. Helen Hutton is appointed as Business Unit Director for...

Lucid’s Right Royal Bake-Off

Lucid joined in on the royal wedding fervour today by celebrating the impending nuptials with a Royal Bake-off, producing cakes fit for the Queen and the new Princess. Lucid love...

Lucid’s magic touch is recognised as they make the shortlist in five different categories for Communiqué 2018

Lucid has been working its magic with its clients again!Four of their pioneering programmes have been shortlisted as finalists for this year’s Communiqué awards. And they have been shortlisted for...